Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: solvent selection based on physico-chemical characterization

References

• Dunn RL, English JP, Cowsar DR & Vanderbilt DP. 1990. Biodegradable in-situ forming implants and methods of producing the same, Us Patent 4,938,763. July 3.
   Google Scholar
• Hatefi A, Amsden B. 2002. Biodegradable injectable in situ forming drug delivery systems. J Control Release, 80:9–28.
   PubMed Web of Science ®Google Scholar
• Jain RA. 2000. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials, 21:2475–2490.
   PubMed Web of Science ®Google Scholar
• Shah NH, Railkar AS, Chen FC, Tarantino R, Kumar S, Murjani, M, Palmer, D, Infeld, MH, Malick, AW. 1993. A biodegradable injectable implant for delivering micro and macromolecules using poly (lactic-co-glycolic) acid (PLGA) copolymers. J Control Release 27:139–147.
   Web of Science ®Google Scholar
• Deadman CM, Kellaway IW, Yasin M, Dickinson PA, Murdan S. 2007. An investigation into the influence of drug lipophilicity on the in vivo absorption profiles from subcutaneous microspheres and in situ forming depots. J Control Release, 122:79–85.
   PubMed Web of Science ®Google Scholar
• Ravivarapu HB, Moyer KL, Dunn RL. (2000). Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int J Pharm, 194:181–191.
   PubMed Web of Science ®Google Scholar
• Wang L, Kleiner L, Venkatraman S. (2003). Structure formation in injectable poly(lactide-co-glycolide) depots. J Control Release, 90:345–354.
   PubMed Web of Science ®Google Scholar
• Packhaeuser CB, Schnieders J, Oster CG, Kissel T. (2004). In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm, 58:445–455.
   PubMed Web of Science ®Google Scholar
• Chen G, Junnarkar, G. 2008 Alzamer Depot bioerodible polymer technology. In: Rathbone MJ, Hadgraft, J, Roberts MS, Lane EM, editors. Modified-release drug delivery technology. Vol. 2. New York, USA: Informa Helath care, p.215–225, 703., Vol.2.
   Google Scholar
• Omura S. (2008). Ivermectin: 25 years and still going strong. Int J Antimicrob Agents, 31:91–98.
   PubMed Web of Science ®Google Scholar
• Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y et al. 2006. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res, 23:1144–1156.
   PubMed Web of Science ®Google Scholar
• Gokbulut C, Karademir U, Boyacioglu M, McKellar QA. 2006. Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. Vet Parasitol, 135:347–354.
   PubMed Web of Science ®Google Scholar
• González Canga A, Sahagún Prieto AM, José Diez Liébana M, Martínez NF, Vega MS, Vieitez JJ. 2009. The pharmacokinetics and metabolism of ivermectin in domestic animal species. Vet J, 179:25–37.
   PubMed Web of Science ®Google Scholar
• Anderson JM, Shive MS. 1997 Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliver Rev, 8:5–24.
   Google Scholar
• Legrand P, Lesieur S, Bochot A, Gref R, Raatjes W, Barratt G et al. 2007. Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation. Int J Pharm, 344:33–43.
   PubMed Web of Science ®Google Scholar
• Matschke C, Isele U, van Hoogevest P, Fahr A. 2002. Sustained-release injectables formed in situ and their potential use for veterinary products. J Control Release, 85:1–15.
   PubMed Web of Science ®Google Scholar
• Liu J, Chang, Z, Sun, X, Shen S, Lei C & Liu H. 2006 Impurity effects on the crystallization of avermectin B1a. J Cryst Growth, 291:448–454.
   Web of Science ®Google Scholar
• Huggins, ML. 1942. The viscosity of diluted solutions of long-chain molecules Iv. Dependence of concentration. J Am Chem Soc, 64, 2716–2718.
   Web of Science ®Google Scholar
• Brodbeck KJ, DesNoyer JR, McHugh AJ. 1999. Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. J Control Release, 62:333–344.
   PubMed Web of Science ®Google Scholar
• Graham PD, Brodbeck KJ, McHugh AJ. 1999. Phase inversion dynamics of PLGA solutions related to drug delivery. J Control Release, 58:233–245.
   PubMed Web of Science ®Google Scholar
• Kranz H Bodmeier R. 2008. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles. Eur J Pharm Sci, 34:164–172.
   PubMed Web of Science ®Google Scholar
• Shively ML, Coonts BA, Renner WD, Southard JL, Bennett, AT. 1995. Physico-chemical characterization of a polymeric injectable implant delivery system. J Control Release, 33, 237–243.
   Web of Science ®Google Scholar
• Dong WY, Körber M, López Esguerra V, Bodmeier R. 2006. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems. J Control Release, 115:158–167.
   PubMed Web of Science ®Google Scholar
• Kranz H, Brazeau GA, Napaporn J, Martin RL, Millard W, Bodmeier R. 2001. Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. Int J Pharm, 212:11–18.
   PubMed Web of Science ®Google Scholar
• Royals MA, Fujita SM, Yewey GL, Rodriguez J, Schultheiss PC, Dunn RL. 1999. Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys. J Biomed Mater Res, 45:231–239.
   PubMed Web of Science ®Google Scholar
• Löffler D, Ternes TA. 2003. Determination of acidic pharmaceuticals, antibiotics and ivermectin in river sediment using liquid chromatography-tandem mass spectrometry. J Chromatogr A, 1021:133–144.
   PubMed Web of Science ®Google Scholar
• Lambert WJ, Peck, KD. 1995 Development of an in situ forming biodegradable poly-lactide-co-glycolide system for the controlled release of proteins. J. Control. Release, 33, 189–195.
   Web of Science ®Google Scholar
• Hansen CM. 1967 The three dimensional solubility parameter-key to paint component affinities: Ii and Iii. J Paint Technol, 39, 505–514.
   Google Scholar
• Hansen CM. 2007. Hansen solubility parameters: A user’s handbook. New York: CRC Press, 1–24.
   Google Scholar
• Alfrey T. 1947 The influence of solvent composition on the specific viscosities of polymer solutions. J Colloid Interf Sci, 2:99–114.
   Web of Science ®Google Scholar
• Rungseevijitprapa W, Bodmeier R. 2009. Injectability of biodegradable in situ forming microparticle systems (ISM). Eur J Pharm Sci, 36:524–531.
   PubMed Web of Science ®Google Scholar
• Wang L, Venkatraman S, Kleiner L. 2004. Drug release from injectable depots: two different in vitro mechanisms. J Control Release, 99:207–216.
   PubMed Web of Science ®Google Scholar
• Kempe S, Metz H, Mäder K. 2008. Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process. J Control Release, 130:220–225.
   PubMed Web of Science ®Google Scholar
• Körber M, Bodmeier R. 2008. Development of an in situ forming PLGA drug delivery system I. Characterization of a non-aqueous protein precipitation. Eur J Pharm Sci, 35:283–292.
   PubMed Web of Science ®Google Scholar
• Siepmann J, Göpferich A. 2001. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev, 48:229–247.
   PubMed Web of Science ®Google Scholar
• Hon HC, Singh, RP, Kudchadker, AP. 1976 Vapor pressure-boiling point measurements of five organic substances by twin ebulliometry. JChem Eng. Data, 21, 430–431.
   Web of Science ®Google Scholar